scholarly journals Identifying Molecular Changes in Early Cervical Cancer Samples of Patients That Developed Metastasis

2022 ◽  
Vol 11 ◽  
Author(s):  
Vera de Geus ◽  
Patricia C. Ewing-Graham ◽  
Willem de Koning ◽  
Maurits N. C. de Koning ◽  
Thierry P. P. van den Bosch ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cervical Cancer ◽  
T Cells ◽  
Recurrent Disease ◽  
Early Stage ◽  
Treatment Options ◽  
Molecular Signature ◽  
Recurrent Cervical Cancer ◽  
Increased Risk ◽  
Early Stage Cervical Cancer

Cervical cancer is one of the most common cancers in women worldwide. Patients diagnosed with early-stage cervical cancer have a good prognosis, however, 10-20% suffer from local or distant recurrent disease after primary treatment. Treatment options for recurrent cervical cancer are limited. Therefore, it is crucial to identify factors that can predict patients with an increased risk of recurrence to optimize treatment to prevent the recurrence of cervical cancer. We aimed to identify biomarkers in early-stage primary cervical cancer which recurred after surgery. Formalin-Fixed, Paraffin-Embedded surgical specimens of 34 patients with early-stage cervical cancer (FIGO 2009 stage 1B1) and 7 healthy controls were analyzed. Targeted gene expression profiling using the PanCancer IO 360 panel of NanoString Technology was performed. The findings were confirmed by performing immunohistochemistry stainings. Various genes, namely GLS, CD36, WNT5a, HRAS, DDB2, PIK3R2, and CDH2 were found to be differentially highly expressed in primary cervical cancer samples of patients who developed distant recurrence. In addition, The relative infiltration score of CD8+ T cells, CD80+CD86+ macrophages, CD163+MRC1+ macrophages, and FOXP3+IL2RA+ regulatory T cells were significantly higher in this group of samples. In contrast, no significant differences in gene expression and relative immune infiltration were found in samples of patients who developed local recurrence. The infiltration of CD8 and FOXP3 cells were validated by immunohistochemistry using all samples included in the study. We identified molecular alterations in primary cervical cancer samples from patients who developed recurrent disease. These findings can be utilized towards developing a molecular signature for the early detection of patients with a high risk to develop metastasis.

scholarly journals Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer

2010 ◽  
Vol 116 (3) ◽  
pp. 539-543 ◽  
Author(s):  
Rebecca Brooks ◽  
Nora Kizer ◽  
Loan Nguyen ◽  
Atthapon Jaishuen ◽  
Karolyn Wanat ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Early Stage ◽  
Nodal Metastases ◽  
Increased Risk ◽  
Early Stage Cervical Cancer

scholarly journals Pembrolizumab in cervical cancer: latest evidence and clinical usefulness

2017 ◽  
Vol 9 (6) ◽  
pp. 431-439 ◽  
Author(s):  
Edith Borcoman ◽  
Christophe Le Tourneau
Keyword(s):  
Cervical Cancer ◽  
Checkpoint Inhibitors ◽  
Early Stage ◽  
Precancerous Lesions ◽  
Treatment Options ◽  
Hpv Vaccination ◽  
Developed Countries ◽  
Clinical Usefulness ◽  
Early Stage Cervical Cancer ◽  
Tumor Types

Cervical cancer is the fourth most common cause of cancer-related deaths in women worldwide. With the development of detection of precancerous lesions and preventive human papillomavirus (HPV) vaccination program, a survival improvement has been observed in these patients in developed countries, although disparities in accessibility to treatments exist across countries. While early-stage cervical cancer can be curable with surgery, prognosis of patients who recur remains poor, with limited treatment options. In this latter setting, recently, bevacizumab, an antiangiogenic monoclonal antibody targeting vascular endothelial growth factor (VEGF), has been shown to improve overall survival in combination with chemotherapy as compared with chemotherapy alone. No standard treatments exist beyond this treatment regimen. New effective treatments are therefore much needed in this setting. Immunotherapy has represented a breakthrough in recent years in oncology, with antitumor activity reported with immune-checkpoint inhibitors in a variety of tumor types. We discuss here the latest evidence and clinical usefulness of pembrolizumab, anti-PD-1 checkpoint inhibitor, in the treatment of advanced cervical cancer.

Gene expression in early stage cervical cancer

2008 ◽  
Vol 108 (3) ◽  
pp. 520-526 ◽  
Author(s):  
Petra Biewenga ◽  
Marrije R. Buist ◽  
Perry D. Moerland ◽  
Emiel Ver Loren van Themaat ◽  
Antoine H.C. van Kampen ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cervical Cancer ◽  
Early Stage ◽  
Early Stage Cervical Cancer

scholarly journals Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer

2008 ◽  
Vol 3 ◽  
pp. BMI.S570 ◽  
Author(s):  
John P. Kirkpatrick ◽  
Zahid N. Rabbani ◽  
Rex C. Bentley ◽  
Matt E. Hardee ◽  
Seth Karol ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Early Stage ◽  
Univariate Analysis ◽  
Tumor Hypoxia ◽  
Multivariable Analysis ◽  
Distant Metastases ◽  
Lymph Node Status ◽  
Increased Risk ◽  
Caix Expression ◽  
Early Stage Cervical Cancer

Tumor hypoxia is associated with adverse outcome in many malignancies. The goal of this study was to determine if elevated expression of carbonic anhydrase IX (CAIX), a biomarker of hypoxia, predicts for recurrence in early-stage cervical cancer. The charts of all patients with early-stage cervical cancer, primarily FIGO IB, treated by radical hysterectomy at our institution from 1988–2001 were reviewed. Adequate pathologic specimens from patients who recurred or who had at least three years follow-up and remained disease-free were stained for CAIX. An immunohistochemical score (IHC) was generated from the extent/intensity of staining. Outcome, as measured by freedom from recurrence (FFR), distant metastases (FFDM) and local recurrence (FFLR), was analyzed as a function of age, IHC, lymph node status (LN) and histology. Forty-two relapsing patients and 76 non-relapsing patients were evaluated. In univariate analysis, +LN, though not IHC or histology, was a significant predictor of any recurrence. Both +LN and higher IHC were associated with decreased FFDM but not FFLR. Patients with both +LN and elevated IHC more frequently exhibited distant metastases as first site of failure (5-year FFDM 50%) than patients with only +LN, elevated IHC or neither feature (70, 85 and 95%, respectively, p = 0.0004). In multivariable analysis, only +LN was significantly associated with poorer FFDM (hazard ratio 4.6, p = 0.0015) though there was a strong trend with elevated CAIX expression (p = 0.069). Elevated CAIX expression is associated with more frequent distant metastases in early-stage cervical cancer, suggesting that patients with this characteristic may benefit from more aggressive treatment.

Patients with early-stage cervical cancer have an increased risk of preterm birth in a population-based cohort study

2021 ◽  
Vol 162 ◽  
pp. S33
Author(s):  
Roni Nitecki ◽  
Katherine Stewart ◽  
Shuangshuang Fu ◽  
Terri Woodard ◽  
Larissa Meyer ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cohort Study ◽  
Preterm Birth ◽  
Early Stage ◽  
Population Based ◽  
Increased Risk ◽  
Early Stage Cervical Cancer

scholarly journals Current management of stage IB2 and bulky IIA, locally advanced, and recurrent cervical carcinoma

2011 ◽  
pp. 117-128
Author(s):  
Karen K. Lo ◽  
Anne O. Rodriguez ◽  
Janice Ryu ◽  
Vijay P. Khatri
Keyword(s):  
Cervical Cancer ◽  
Cervical Carcinoma ◽  
Early Stage ◽  
Treatment Options ◽  
Locally Advanced ◽  
Distant Metastases ◽  
Early Disease ◽  
Recurrent Cervical Cancer ◽  
Therapeutic Modalities ◽  
Risk Of Death

Cervical cancer is one of the most common cancers affecting women, with most early disease treated with either surgery or radiation alone with an 85%–95% 5-year survival rate, while locally advanced cervical cancer (LACCA) requires multiple therapeutic modalities. The clear distinction between early and LACCA has, in recent years, blurred as stages IB2 and bulky IIA, which were traditionally thought of as early disease, have been shown to require more treatment than other early stage cervical cancer. LACC is now treated with cisplatin-based chemoradiation therapy based upon the results of the randomized co-operative group studies that demonstrated reduced relative risk of death, local failure rates, and incidence of distant metastases. Recurrent cervical cancer is devastating and is rarely cured. Treatment of recurrent cervical carcinoma depends on the previous therapy, the site of recurrence, and the extent of the recurrence. This review will outline the treatment options for the various stages of cervical cancer.

Sign in / Sign up

Export Citation Format

Share Document